◆英語タイトル:Cevec Pharmaceuticals GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013918
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Cevec Pharmaceuticals GmbH (Cevec) is a healthcare products company that offers production of biopharmaceuticals. The company produces recombinant glycoproteins and gene therapy vectors. It utilizes its CAP-Go technology developed expression system based on human cells, for the production of complexly glycosylated molecules including coagulation factors and other plasma proteins. Cevec’s CAP-GT cell lines provide a novel platform for the industrial production of adenoviral vectors, AAV and lentiviral vectors. The company provides CGMP manufacturing, cell line development, process development, and contract manufacturing services among others. It out-licenses its expression technology platform and product candidates through partnerships with biotechnology and pharmaceutical companies. Cevec is headquartered in Cologne, Germany.
Cevec Pharmaceuticals GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CEVEC Pharma Raises USD4.9 Million in Financing Round 11
Cevec Pharma Raises US$3.6 Million In Extended Series C Financing 13
CEVEC Pharma Raises US$8.6 Million In Series C Financing 15
Partnerships 16
Cevec Pharma to Enter into Agreement with PlasmidFactory 16
Catalent Pharma Enters Into Co-Development Agreement With Cevec Pharma 17
CEVEC Pharma Enters Into Technology Integration Agreement With Catalent Pharma 18
Licensing Agreements 19
Provecs Medical and medac Gesellschaft Enter into Licensing Agreement with CEVEC Pharma 19
NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 20
BioLamina Enters into Licensing Agreement with Cevec Pharma 21
Paragon Bioservices Enters into Licensing Agreement with CEVEC Pharma 22
Beckman Research Institute Enters into Licensing Agreement with CEVEC Pharma 23
CellGenix Enters into Licensing Agreement with Cevec Pharma 24
CEVEC Pharma Enters into Licensing Agreement with Genethon 25
CEVEC Pharma Enters into Licensing Agreement with Biotest 26
Vibalogics Enters into Licensing Agreement with Cevec Pharma for CAP Technology 27
Cevec Pharma Enters Into Licensing Agreement With Vakzine Projekt Management For CMV Dense Body Technology 28
Cevec Pharma Enters Into Licensing Agreement With Yuhan To Develop Therapeutic Proteins 29
Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 30
CEVEC Pharma Announces Licensing Agreement With Paragon Bioservices For Proprietary Human Cell Lines 31
Cevec Pharmaceuticals GmbH – Key Competitors 32
Cevec Pharmaceuticals GmbH – Key Employees 33
Cevec Pharmaceuticals GmbH – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Legal and Regulatory 35
Oct 27, 2016: CEVEC Submits Biologics Master File (BB-MF) for CAP Technology to the U.S. FDA 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cevec Pharmaceuticals GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CEVEC Pharma Raises USD4.9 Million in Financing Round 11
Cevec Pharma Raises US$3.6 Million In Extended Series C Financing 13
CEVEC Pharma Raises US$8.6 Million In Series C Financing 15
Cevec Pharma to Enter into Agreement with PlasmidFactory 16
Catalent Pharma Enters Into Co-Development Agreement With Cevec Pharma 17
CEVEC Pharma Enters Into Technology Integration Agreement With Catalent Pharma 18
Provecs Medical and medac Gesellschaft Enter into Licensing Agreement with CEVEC Pharma 19
NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 20
BioLamina Enters into Licensing Agreement with Cevec Pharma 21
Paragon Bioservices Enters into Licensing Agreement with CEVEC Pharma 22
Beckman Research Institute Enters into Licensing Agreement with CEVEC Pharma 23
CellGenix Enters into Licensing Agreement with Cevec Pharma 24
CEVEC Pharma Enters into Licensing Agreement with Genethon 25
CEVEC Pharma Enters into Licensing Agreement with Biotest 26
Vibalogics Enters into Licensing Agreement with Cevec Pharma for CAP Technology 27
Cevec Pharma Enters Into Licensing Agreement With Vakzine Projekt Management For CMV Dense Body Technology 28
Cevec Pharma Enters Into Licensing Agreement With Yuhan To Develop Therapeutic Proteins 29
Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 30
CEVEC Pharma Announces Licensing Agreement With Paragon Bioservices For Proprietary Human Cell Lines 31
Cevec Pharmaceuticals GmbH, Key Competitors 32
Cevec Pharmaceuticals GmbH, Key Employees 33
Cevec Pharmaceuticals GmbH, Subsidiaries 34